Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center.
Clinical-stage CAR-T company is actively recruiting patients to evaluate SynKIR™-110, a new treatment candidate for ovarian cancer, mesothelioma, and cholangiocarcinoma PHILADELPHIA, March 7, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company developing the novel KIR-CAR platform technology, today announced that it has activated a second clinical site for its STAR-101 Phase 1 clinical trial at The University of Texas MD Anderson Cancer Center. STAR-101 is a multi-center clinical trial designed to evaluate Verismo Therapeutic’s lead candidate, SynKIR™-110, for the treatment of mesothelin-overexpressing ovarian cancer, malignant pleural mesothelioma, and cholangiocarcinoma. “This milestone marks the steady progress towards our goal of bringing SynKIR™-110 to as many patients as possible,” said Dr. Bryan Kim, Co-Founder and CEO of Verismo Therapeutics. “We are grateful for the opportunity to work with Dr. Mehmet Altan at MD Anderson to bring us closer to that goal.” Verismo achieved clearance from the FDA to initiate this multi-center clinical trial for SynKIR™-110 and has partnered with the Hospital of the University of Pennsylvania as the first clinical site. Verismo has previously announced that SynKIR™-110 received Orphan Drug Designation and Fast Track Designation for the treatment of mesothelin-expressing mesotheliomas. For more information about the STAR-101 clinical trial, please visit ClinicalTrials.gov NCT05568680. About the KIR-CAR Platform About Verismo Therapeutics CONTACT: Raymond Luke, raymond.luke@verismotherapeutics.com View original content to download multimedia:https://www.prnewswire.com/news-releases/verismo-therapeutics-announces-opening-of-second-clinical-site-for-star-101-phase-1-trial-302082215.html SOURCE Verismo Therapeutics |